Anesthetic Management of Factor XIII Deficiency During EDAS: Case Report and Review

Managing patients with Factor XIII (FXIII) deficiency during surgical procedures presents unique challenges for anesthetic and perioperative teams. A recent case report and literature review published in Cureus highlights the complexities of administering anesthesia to a patient with this rare coagulation defect undergoing encephaloduroarteriosynangiosis (EDAS), a neurosurgical procedure.

Factor XIII deficiency is a rare bleeding disorder that can lead to significant hemorrhagic complications. Because FXIII is responsible for stabilizing fibrin clots, its absence or deficiency results in clots that are easily broken down, increasing the risk of delayed bleeding after an initial injury or surgical intervention.

Diagnostic Challenges of Factor XIII Deficiency

One of the most critical aspects of FXIII deficiency is that it often evades detection during standard preoperative screenings. Typical coagulation tests, such as prothrombin time (PT) and activated partial thromboplastin time (aPTT), usually reveal normal findings in these patients.

This diagnostic gap can lead to unexpected bleeding episodes. For example, a 64-year-old man reported in a separate case study presented with FXIII deficiency and a bleeding tendency that was difficult to diagnose because his standard coagulation tests appeared normal.

Perioperative and Anesthetic Management

The Cureus report emphasizes that there is a paucity of literature regarding the perioperative management of FXIII deficiency specifically within neurosurgical contexts. The case of the patient undergoing EDAS serves as a critical reference for how to navigate these risks.

Management typically involves ensuring that factor levels are maintained at a safe threshold to prevent hemorrhage. In related coagulation disorders, such as hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency), and type 1 von Willebrand disease, guidelines suggest maintaining factor levels at 50% or above.

For these other conditions, the recommended window for maintaining these levels extends from the time of catheter insertion until 12 to 24 hours after the catheter is removed.

Impact on Specialized Procedures

The risks associated with FXIII deficiency extend to various medical scenarios, including neuraxial analgesia. A case report published in Case Reports in Anesthesiology detailed the management of a 28-year-old pregnant woman with severe congenital FXIII deficiency who had a history of hemorrhagic stroke and required an epidural during active labor.

These cases underscore the necessity of a multidisciplinary approach, involving hematologists and anesthesiologists, to create a tailored management algorithm. This is especially vital in high-risk areas such as the brain or the spinal column, where bleeding can have devastating neurological consequences.

Summary of Clinical Considerations

• Standard coagulation tests (PT and aPTT) are typically normal and cannot be used to rule out FXIII deficiency.
• Patients may exhibit a significant bleeding tendency that is challenging to diagnose without specific FXIII testing.
• Perioperative management in neurosurgery is under-documented, necessitating a cautious, case-by-case approach.
• Maintaining factor levels above 50% is a benchmark used in similar coagulation deficiencies to mitigate bleeding risks during and after invasive procedures.